Keyphrases
Retrospective Analysis
100%
Organ Dysfunction
100%
Immune Checkpoint Inhibitors
100%
Immune-related Adverse Events
85%
Chronic Obstructive Pulmonary Disease
57%
Congestive Heart Failure
57%
Cirrhosis
42%
Progression-free Survival
42%
Chronic Kidney Disease
42%
Clinical Trials
28%
Patient Characteristics
28%
Treatment Characteristics
28%
Disease Groups
28%
Heart Failure
14%
Fisher's Exact Test
14%
Comorbidity
14%
Treatment Outcome
14%
Wilcoxon Rank Sum Test
14%
Categorical Variables
14%
Adverse Outcomes
14%
Descriptive Statistics
14%
Log-rank Test
14%
Time to Onset
14%
One Dose
14%
Stage II-III
14%
Number of Hospitalization
14%
Independent Sample T-test
14%
Stage IV Disease
14%
Local Treatment
14%
Kaplan-Meier
14%
Acute Exacerbation of COPD (AECOPD)
14%
Solid Organ Malignancy
14%
Medicine and Dentistry
Immune Checkpoint Inhibitor
100%
Immune-Related Adverse Events
85%
Chronic Obstructive Pulmonary Disease
71%
Congestive Heart Failure
57%
Liver Cirrhosis
42%
Progression Free Survival
42%
Chronic Kidney Disease
42%
Disease
28%
Clinical Trial
28%
Patient Characteristics
28%
Cancer
14%
Disease Exacerbation
14%
Student T Test
14%
Rank Sum Test
14%
Heart Failure
14%
Fisher Exact Test
14%
Adverse Outcome
14%
Log Rank Test
14%
Local Therapy
14%
Nursing and Health Professions
Adverse Event
100%
Obstructive Lung Disease
83%
Congestive Heart Failure
66%
Liver Cirrhosis
50%
Chronic Kidney Failure
50%
Progression Free Survival
50%
Disease
33%
Student T Test
16%
Rank Sum Test
16%
Disease Exacerbation
16%
Comorbidity
16%
Log Rank Test
16%
Heart Failure
16%
Fisher Exact Test
16%
Adverse Outcome
16%
Local Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Adverse Event
85%
Chronic Obstructive Lung Disease
71%
Congestive Heart Failure
57%
Liver Cirrhosis
42%
Progression Free Survival
42%
Chronic Kidney Failure
42%
Disease
28%
Clinical Trial
28%
Disease Exacerbation
14%
Comorbidity
14%
Heart Failure
14%
Adverse Outcome
14%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
Progression Free Survival
42%
Clinical Trial
28%
Mann-Whitney U Test
14%
Comorbidity
14%